Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90033


This pilot research trial studies quantitative imaging metrics derived from contrast enhanced computed tomography (CECT) in enhancing assessment of disease status in patients with kidney cancer. Quantitative imaging is the extraction of quantifiable features from radiological images for the assessment of disease status. Collecting quantitative imaging metrics from CECT imaging may help doctors predict tumor aggressiveness and nuclear grade (tumor stage) and assess treatment response and prognosis in cancer imaging.

Study summary:

PRIMARY OBJECTIVES: I. To investigate the role of quantitative imaging metrics (QIM) as a potential DIAGNOSTIC biomarker. II. To investigate if QIM parameters can differentiate clear cell renal cell carcinoma (RCC) from papillary RCC. III. To evaluate the tumor grade of the target lesion as assessed by QIM from CECT for agreement with the pathological (Fuhrman) grade. IV. To investigate the role of QIM as a potential PROGNOSTIC biomarker. V. To develop a novel method of calculating renal tumor contact surface area (CSA) using advanced image-processing technology (MATLAB®, 3 dimension [D] Synapse) and predict peri-operative variables such as blood loss, operative time and post-operative estimated glomerular filtration rate (eGFR) in patients undergoing partial nephrectomy (PN). VI. To develop QIM that would help in predicting postoperative functional outcomes such as predicted surgically resected volume and postoperative glomerular filtration rate (GFR). OUTLINE: Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.


Inclusion Criteria: - Subjects with a renal mass who are scheduled for surgery for presumed RCC - Subjects scheduled for standard of care contrast enhanced CT examination at USC Norris Comprehensive Cancer Center - Subjects competent to sign study specific written informed consent Exclusion Criteria: - Subjects who are pregnant - Subjects who cannot consent for themselves



Primary Contact:

Principal Investigator
Vinay Duddalwar
University of Southern California

Backup Contact:


Location Contact:

Los Angeles, California 90033
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.